Description: MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Home Page: mbxbio.com
11711 N. Meridian Street
Carmel,
IN
46032
United States
Phone:
(317) 659-0200
Officers
| Name | Title |
|---|---|
| Mr. Peter Kent Hawryluk MBA | CEO, President & Director |
| Mr. Richard B. Bartram CPA | Chief Financial Officer |
| Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D. | Chief Scientific Officer |
| Mr. Matt Gambino | Vice President of Marketing |
| Ms. Michelle Graham | Chief Human Resources Officer |
| Dr. Salomon Azoulay | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-09-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |